louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05443893: Artificial Intelligence in Kinematics Analysis
Official title: Application Research of Key Points Detection Technology of Artificial Intelligence in Kinematics Analysis
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Gait
Lead sponsor: Peking University Third Hospital
Sponsor class: OTHER
First posted: 2022-07-05
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Normal gait subjects and abnormal gait subjects

Brief summary: 1. Establish data sets. The private data set includes relevant parameters including video of the subject's gait and standard methods for kinematic analysis;
2. Develop new models. Based on public and private data sets, the kinematic analysis model of human key point detection is further developed.
3. Test the new model. By comparing the parameters with the standard method, the accuracy of the model was verified, and the kinematics analysis model of artificial intelligence with accuracy above 98% was obtained

Detailed description: Artificial intelligence human key point detection model mainly has traditional algorithm, "top-down" algorithm and "bottom-up" algorithm three methods, three methods have advantages. This project will comprehensively use the above three methods to conduct algorithm and parameter debugging in the public data set and test in the private data set, so as to obtain the most suitable human key point recognition method for gait analysis

Eligibility criteria: Inclusion Criteria:

* 1. Abnormal gait.
* Can walk 6m or more independently.
* Older than 18.

Exclusion Criteria:

* Fracture may be aggravated by walking in the acute stage or early postoperative stage. Have heart, lung, liver and kidney And other serious diseases, heart function grading greater than GRADE I (NYHA), respiratory failure and other symptoms and signs or Check the results.
* The mental and psychological state cannot cooperate with the completion of the experiment.
* High risk of falls (Berg score ≤20）
* Gait kinematics analysis equipment cannot be used together.

Primary outcomes:
measure: Gait related parameters
timeFrame: 30mins
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05586893: Acupuncture and Skin Temperature Behavior
Official title: Skin Temperature Behavior by Infrared Thermography After Application of Electroacupuncture and Acupuncture
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Thermography
Acupuncture Therapy
Electroacupuncture
Lead sponsor: University of Sao Paulo
Sponsor class: OTHER
First posted: 2022-10-19
Enrollment: 54
Sex: ALL
Minimum age (years): 18
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Objective: Evaluating the behavior of skin temperature through infrared thermography after application of acupuncture and electroacupuncture in Weizhong (B40) and Kunlun (B60) acupunctures points. Methods: A single-blind randomized clinical trial was performed with 54 participants of both sexes, mean of 21.88±2.53 years, randomized into three groups (n=18): electroacupuncture (EAG), acupuncture (AG) and control (CG). The application was bilateral in the acupoints (B60 and B40), for 20 minutes. The skin temperature of the lower limbs was measured at the following times: before application, 10 minutes of application, 20 minutes of application and 10 minutes after needle removal.


Eligibility criteria: Inclusion Criteria:

* Both sexes;
* Aged between 18-30 years;
* Good general health;

Exclusion Criteria:

* Pregnant women;
* Hemophiliacs;
* Smokers;
* Patients with severe cardiovascular diseases.

Primary outcomes:
measure: Skin temperature
timeFrame: 30 minutes after the first assessment (P30)
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01815593: The Value of Enhanced External Counterpulsation on Erectile Dysfunction
Official title: A Prospective, Randomized Study of Enhanced External Counterpulsation for Patients With Erectile Dysfunction
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Erectile Dysfunction
Keywords: Erectile Dysfunction
Vascular Endothelium
Counterpulsation, External
Lead sponsor: First Affiliated Hospital, Sun Yat-Sen University
Sponsor class: OTHER
First posted: 2013-03-21
Enrollment: 120
Sex: MALE
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Patients with erectile dysfunction are assigned to two groups in parallel for the duration of the study
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to investigate the efficacy of Enhanced External Counterpulsation (EECP) in patients with erectile dysfunction

Detailed description: Patients with erectile dysfunction will be randomized into two groups: EECP intervention or not. Erectile function, hemodynamic parameters, vascular endothelial function will be measured and compared.

Eligibility criteria: Inclusion Criteria:

1. men over 18 years old;
2. provide signed informed consent;
3. existence of erectile dysfunction
4. agree not to use any other erectile dysfunction treatment at least one month;

Exclusion Criteria:

1. history of long drug abuse;
2. pelvic, spine, brain trauma or surgery;
3. endocrine, liver, lung, kidney disease, malignancies, hematological disorders;
4. abnormal urogenital status, such as small testicle (\<2cm), penile plaques;

Primary outcomes:
measure: Erectile function evaluated by International Index of Erectile Function-5 questionnaire
timeFrame: 7 weeks
Secondary outcomes:
measure: Endothelial function
timeFrame: 7 weeks
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: First Affiliated Hospital, Sun Yat-sen University
state: Guangdong
Study officials:
affiliation: First Affiliated Hospital, Sun Yat-Sen University
name: Yan Zhang, M. D.
role: STUDY_DIRECTOR
References:
citation: El-Sakka A, Morsy A, Fagih B. Enhanced external counterpulsation in patients with coronary artery disease-associated erectile dysfunction. Part I: effects of risk factors. J Sex Med. 2007 May;4(3):771-779. doi: 10.1111/j.1743-6109.2007.00458.x. Epub 2007 Apr 13.
Clinical trial NCT02388893: Endocarditis Registry of the University Hospital of Cologne (ER-UHC)
Official title: Endocarditis Registry of the University Hospital of Cologne (ER-UHC)
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Infective Endocarditis
Lead sponsor: University of Cologne
Sponsor class: OTHER
First posted: 2015-03-17
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Adult patients with definitive IE

Brief summary: As recommended in the Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (IE) patients with IE should be evaluated and managed by a multispecialty team including an cardiologist, infectious disease specialist, and cardiac surgeon. Our registry is a prospective, national registry of patients with IE. From January 2013 data from endocarditis board were prospectively recorded using standard definitions during the hospitalization. Patient demographics, clinical, laboratory, and imaging data at the time of IE diagnosis, as well as treatment outcomes were entered into the ER-UHC database.

Detailed description: The primary endpoint will be the 1 year all-cause mortality after treatment begins of IE. We will use 1 year all-cause mortality as the primary endpoint because it has been demonstrated that a period of at least 6 months is necessary to offset the early postoperative mortality related to valve surgery. We also looked at all-cause in-hospital mortality as a secondary endpoint.

Eligibility criteria: Inclusion Criteria:

* All patients with patients with definitive infective endocarditis

Exclusion Criteria:

* childs

Primary outcomes:
measure: All-cause mortality
timeFrame: 1 year
Secondary outcomes:
measure: Inhospital all-cause mortality
timeFrame: 1 month
Other outcomes:
Locations:
city: Cologne
country: Germany
facility: Heart Center of the University of Cologne
Study officials:
affiliation: Heart Center, University of Cologne, Germany
name: Guido Michels, Prof. Dr.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT07009093: Utility of a Mobile Application for Young Women With Breast Cancer
Official title: Utility of a Mobile Application for Young Women With Breast Cancer
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Breast Cancer
Cancer Distress
Keywords: Cancer-related Distress
Breast Cancer
Young Adult Cancer
Lead sponsor: Wake Forest University Health Sciences
Sponsor class: OTHER
Collaborators: name: Atrium Health Levine Cancer Institute
First posted: 2025-06-06
Enrollment: 120
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: This study aims to evaluate the use of mobile technology as a communication tool among patients with breast cancer and measured its effect on patient-reported cancer-related distress, specifically focusing on young women as they often face unique challenges.

Detailed description: This is a prospective, randomized, two stage study. The target population is adult females ≥ 18 and ≤ 45 years of age with breast cancer with a National Comprehensive Cancer Network (NCCN) Distress Thermometer score of distress score ≥ 4. The study will be conducted at Atrium Health Wake Forest Baptist Comprehensive Cancer Center (AHWFBCCC). The hypothesis is that the social connectivity via the Mighty Pro Application, as well as the educational components available in the application, will decrease patients' cancer-related distress. This study aims to evaluate the feasibility of implementing the Mighty Pro Application and measure its efficacy at reducing distress among young women with breast cancer.

Eligibility criteria: Inclusion Criteria:

* Ability to understand and willingness to sign an IRB-approved informed consent
* Age ≥ 18 and ≤ 45 years at the time of consent
* Female
* Established patient at Atrium Health Wake Forest Baptist Comprehensive Cancer Center (AHWFBCCC)
* Histological confirmation of any type and stage (0-IV) of breast cancer
* Screening (baseline) NCCN Distress Thermometer score ≥ 4
* Access to a mobile device for trial purposes and an active email address
* Ability to read and understand the English language. NOTE: The Mighty Pro Application is available in English only.
* As determined by the enrolling Investigator, ability of the participant to understand and comply with study procedures for the entire length of the study

Exclusion Criteria:

- None

Primary outcomes:
measure: Stage 1: Feasibility of Implementation of Mighty Pro App
timeFrame: 26 Weeks
measure: Stage 2: Efficacy of the Mighty Pro App
timeFrame: 26 Weeks
Secondary outcomes:
measure: Efficacy of the Mighty Pro App in Improving Distress Scores
timeFrame: 52 Weeks
measure: Efficacy of the Mighty Pro App in Improving Distress Scores - Quantitative
timeFrame: 52 Weeks
Other outcomes:
Locations:
city: Charlotte
country: United States
facility: Atrium Health Levine Cancer
state: North Carolina
Study officials:
affiliation: Wake Forest University Health Sciences
name: Lejla Hadzikadic-Gusic, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00632593: Trial Comparing Early Complications of Two Techniques in the Laparoscopic Gastric Bypass
Official title: Prospective Randomized Trial Comparing Early Complications of Hand-Sewn Versus Circular Stapled Gastro-Jejunal Anastomosis in Laparoscopic Gastric Bypass
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Obesity
Keywords: Early Complications of both techniques
Fistula rate
Dehiscence rate
reoperation rate and cause
Lead sponsor: Hospital Universitari de Bellvitge
Sponsor class: OTHER
First posted: 2008-03-10
Enrollment: 102
Sex: ALL
Minimum age (years): 21
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to define and evaluate the early complications between two different surgical techniques used to perform a laparoscopic gastric bypass


Eligibility criteria: Inclusion Criteria:

* Body mass Index between 35 with comorbidities and 50 kg/mt2

Exclusion Criteria:

* Body mass index \<35kg7mt2 and \>50kg/mt2

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Barcelona
country: Spain
facility: University Hospital Of Bellvitge
state: Catalonia
Study officials:
affiliation: Hospital Universitari de Bellvitge
name: Leonardo J Silvio, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04488393: Clinical Performance of NIPT in Multiple Gestation Pregnancies
Official title: Clinical Performance of NIPT (Noninvasive Prenatal Testing) in Multiple Gestation Pregnancies (SCMM-T21-110)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Trisomy 21 in Fetus
Lead sponsor: University of Pennsylvania
Sponsor class: OTHER
Collaborators: name: Sequenom, Inc/Laboratory Corporation of America Holdings
First posted: 2020-07-28
Enrollment: 2000
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The Study Population will consist of women 18 years of age and older who underwent testing with a Sequenom NIPT, were pregnant with a multiple gestation at the time of testing and whose pregnancies should have outcome based upon gestational age at the time of testing.

Brief summary: This study plans to evaluate the clinical performance of the MaterniT21 PLUS and/or GENOME Laboratory Developed Test, in the detection of fetal trisomy 21 in circulating cell-free DNA extracted from maternal blood samples obtained from women pregnant with a twin gestation.


Eligibility criteria: Inclusion Criteria:

* subject pregnant with a multiple gestation and received NIPT from Sequenom Laboratories;
* subject was 18 or older at the time of NIPT

Exclusion Criteria:

* none

Primary outcomes:
measure: Determination of sensitivity of NIPT detection of trisomy 21 among a population of women with twin gestations.
timeFrame: time from maternal blood draw to delivery
measure: Determination of specificity of NIPT detection of trisomy 21 among a population of women with twin gestations.
timeFrame: time from maternal blood draw to delivery
Secondary outcomes:
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: University of Pennsylvania
state: Pennsylvania
Study officials:
References:
Clinical trial NCT01953393: The Acute Effects of Low-dose TNF-α on Glucose Metabolism and β-cell Function in Humans
Official title: The Acute Effects of Low-dose TNF-α on Glucose Metabolism and β-cell Function in Humans
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Diabetes Type 2
Lead sponsor: Rigshospitalet, Denmark
Sponsor class: OTHER
Collaborators: name: Copenhagen Muscle Research Centre, Rigshospitalet, Copenhagen, Denmark
name: University of Copenhagen
First posted: 2013-10-01
Sex: MALE
Minimum age (years): 20
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Primary purpose: BASIC_SCIENCE

Brief summary: Type 2 diabetes is characterized by increased insulin resistance and impaired insulin secretion. In addition, type 2 diabetes is associated with low grade inflammation indicated by increased levels of proinflammatory cytokines such as TNF-α. TNF-α has previously been shown to impair peripheral insulin signaling in vitro and in vivo. However, it is unclear whether TNF-α may also affect endogenous glucose production (EGP) during fasting and glucose stimulated insulin secretion (GSIS) in vivo.

We hypothesized that low dose TNF-α would increase EGP and attenuate GSIS. Recombinant human TNF-α or placebo was infused in healthy, non-obese and non-diabetic young men (n=10) during a 4-hour basal period followed by an intravenous glucose tolerance test (IVGTT).


Eligibility criteria: Inclusion Criteria:

* Healthy men
* Age 20-35

Exclusion Criteria:

* obesity (BMI\>25)
* diabetes
* chronic disease

Primary outcomes:
measure: Beta-cell function
timeFrame: Measurements at 0h, 1h, 2h, 3h and 4h during basal period. After glucose bolus infusion, measurements every 1 min for the first 30 min and every 3 mins for the next hour. Last measurement 1,5 hours post- IVGTT
Secondary outcomes:
Other outcomes:
Locations:
city: Copenhagen N
country: Denmark
facility: 1 The Centre of Inflammation and Metabolism, Department of Infectious Diseases and CMRC, Rigshospitalet, Faculty of Health Sciences, University of Copenhagen
Study officials:
affiliation: Rigshospitalet, Denmark
name: Christian P Fischer, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Plomgaard P, Fischer CP, Ibfelt T, Pedersen BK, van Hall G. Tumor necrosis factor-alpha modulates human in vivo lipolysis. J Clin Endocrinol Metab. 2008 Feb;93(2):543-9. doi: 10.1210/jc.2007-1761. Epub 2007 Nov 20.
Clinical trial NCT00538993: Improving Provider Counseling Interventions in HIV Practice
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: HIV Infections
Lead sponsor: Johns Hopkins University
Sponsor class: OTHER
Collaborators: name: University of California, San Francisco
First posted: 2007-10-03
Enrollment: 470
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: Hypothesis: HIV clinicians trained to deliver brief counseling messages and receiving cues from a brief computer survey on risk behaviors of their patients can counsel have an impact on patient's risk behaviors.

Detailed description: This is a randomized controlled study. The purpose of this study is to assess the impact of the cue sheet as an aid to targeted provider behavioral counseling. All enrolled participants are HIV+ adults seen for regular medical care at a site affiliated with the Johns Hopkins AIDS Service. After consenting, participants will take an audio-assisted computer interviews to collect patient risk assessment data. For participants randomized to the intervention arm, the printed output on risk behaviors is then given to the provider along with cues for staged-based counseling for use during the same visit. Participants in the control arm take the same computerized risk assessment but there are no printed cue sheets. Risk behaviors of all participants are assessed at entry, at 6 months, and at 12 months. The main outcome measure is change in HIV transmission behaviors at 12 months for those in the intervention arm compared to the control arm.

Eligibility criteria: Inclusion Criteria:

* HIV seropositive
* English speaking

Exclusion Criteria:

* Cannot give informed consent

Primary outcomes:
measure: Disclosure of HIV status to sex partners; unprotected sexual encounters.
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Baltimore
country: United States
facility: Johns Hopkins University School of Medicine
state: Maryland
Study officials:
affiliation: Johns Hopkins University
name: Emily Erbelding, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00319293: Efficacy of Metformin in Lean Women With Polycystic Ovary Syndrome
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Polycystic Ovary Syndrome
Lead sponsor: Aarhus University Hospital Skejby
Sponsor class: OTHER
Collaborators: name: Aarhus University Hospital
First posted: 2006-04-27
Enrollment: 20
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Insulin resistance is an important feature of the polycystic ovary syndrome,and patiens are successfully treated with the insulin sensitizing agent metformin. The insulin resistance of lean patients with the syndrome is debated. In this study, we will study the change in insulin resistance, metabolic and hormonal factors after 3 months of metformin treatment in lean PCOS women.


Eligibility criteria: Inclusion Criteria:

* PCOS (Rotterdam criteria)
* BMI \< 27
* No medication for 3 months

Exclusion Criteria:

* Pregnancy
* Lactation
* Other endocrinologic disease

Primary outcomes:
measure: Insulin resistance
measure: Hormonal factors
measure: Metabolic factors
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Skejby University Hospital
name: Birgitta Trolle, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00277693: Cardiovascular Protective Effect of Spironolactone in Hemodialysis
Official title: Protective Mechanisms of Aldosterone Antagonists and Their Effects on Cardiovascular Damage in Chronic Renal Failure: Clinical and Experimental Studies
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Hemodialysis
Keywords: hemodialysis
aldosterone
heart failure
spironolactone
Lead sponsor: Universidad de los Andes, Chile
Sponsor class: OTHER
First posted: 2006-01-16
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of the present study is to determine if spironolactone is safe and effective in the treatment of cardiovascular complications in hemodialysis patients.

Detailed description: Cardiovascular complications are common in dialysis patients and comprise up to 50% of deaths in end-stage renal disease population. Hypertension and left ventricle hypertrophy occur in more than 70% of patients undergoing long-term hemodialysis therapy, and both contributes to mortality and morbidity.Recent clinical trials in chronic heart failure and post miocardial infarct heart failure patients have demonstrated a beneficial effect of a mineralocorticoid receptor blocker spironolactone, in adittion to standard therapy (RALES AND EPHESUS studies). The aim of the present study is to evaluate spironolactone treatment in hemodialysis patients.

Eligibility criteria: Inclusion Criteria:

chronic hemodialysys (\> 3 months) anuria (diuresis \<200 mL/day) -

Exclusion Criteria:

Liver failure Insulin dependent diabetes Treatment with adrenergic beta blockers or agonists Treatment with converting-enzime blocker or angiotensin receptor antagonists Cancer

-

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Santiago
country: Chile
facility: Clinica Davila
Study officials:
affiliation: Faculty of Medicine, University Los Andes
name: Luis F Michea, MD PhD
role: STUDY_CHAIR
References:
citation: Michea L, Vukusich A, Gonzalez M, Zehnder C, Marusic ET. Effect of spironolactone on K(+) homeostasis and ENaC expression in lymphocytes from chronic hemodialysis patients. Kidney Int. 2004 Oct;66(4):1647-53. doi: 10.1111/j.1523-1755.2004.00931.x.
citation: Hasegawa T, Nishiwaki H, Ota E, Levack WM, Noma H. Aldosterone antagonists for people with chronic kidney disease requiring dialysis. Cochrane Database Syst Rev. 2021 Feb 15;2(2):CD013109. doi: 10.1002/14651858.CD013109.pub2.